MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

التفاصيل البيبلوغرافية
العنوان: MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199
المؤلفون: Benito, Juliana M., Godfrey, Laura, Kojima, Kensuke, Hogdal, Leah, Wunderlich, Mark, Geng, Huimin, Marzo, Isabel, Harutyunyan, Karine G., Golfman, Leonard, North, Phillip, Kerry, Jon, Ballabio, Erica, Chonghaile, Triona Ní, Gonzalo, Oscar, Qiu, Yihua, Jeremias, Irmela, Debose, LaKiesha, O\u2019Brien, Eric, Ma, Helen, Zhou, Ping, Jacamo, Rodrigo, Park, Eugene, Coombes, Kevin R., Zhang, Nianxiang, Thomas, Deborah A., O\u2019Brien, Susan, Kantarjian, Hagop M., Leverson, Joel D., Kornblau, Steven M., Andreeff, Michael, Müschen, Markus, Zweidler-McKay, Patrick A., Mulloy, James C., Letai, Anthony, Milne, Thomas A., Konopleva, Marina
المصدر: Cell Reports
Zaguán. Repositorio Digital de la Universidad de Zaragoza
instname
Cell Reports, Vol 13, Iss 12, Pp 2715-2727 (2015)
Zaguán: Repositorio Digital de la Universidad de Zaragoza
Universidad de Zaragoza
بيانات النشر: The Authors. Published by Elsevier Inc.
مصطلحات موضوعية: leukemias, Sulfonamides, MLL/AF4, apoptosis pathways, Histone-Lysine N-Methyltransferase, Mice, SCID, DOT1L, Bridged Bicyclo Compounds, Heterocyclic, Methylation, Article, Genes, bcl-2, Mice, lcsh:Biology (General), Proto-Oncogene Proteins c-bcl-2, Mice, Inbred NOD, Cell Line, Tumor, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, hemic and lymphatic diseases, bcl-2 family members, Animals, Humans, H3K79 methylation, neoplasms, lcsh:QH301-705.5, Myeloid-Lymphoid Leukemia Protein
الوصف: Summary Targeted therapies designed to exploit specific molecular pathways in aggressive cancers are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as the t(4;11) translocation cause aggressive leukemias that are refractory to conventional treatment. The t(4;11) translocation produces an MLL/AF4 fusion protein that activates key target genes through both epigenetic and transcriptional elongation mechanisms. In this study, we show that t(4;11) patient cells express high levels of BCL-2 and are highly sensitive to treatment with the BCL-2-specific BH3 mimetic ABT-199. We demonstrate that MLL/AF4 specifically upregulates the BCL-2 gene but not other BCL-2 family members via DOT1L-mediated H3K79me2/3. We use this information to show that a t(4;11) cell line is sensitive to a combination of ABT-199 and DOT1L inhibitors. In addition, ABT-199 synergizes with standard induction-type therapy in a xenotransplant model, advocating for the introduction of ABT-199 into therapeutic regimens for MLL-rearranged leukemias.
Graphical Abstract
Highlights • MLLr ALL blasts express high levels of BCL-2, BAX, and BIM • MLL/AF4 activates BCL2 through H3K79 methylation • MLLr ALL cells are exquisitely sensitive to BCL-2 antagonist ABT-199 • ABT-199 treatment synergizes with H3K79 methylation inhibitors on MLLr samples
Therapies designed to exploit specific molecular pathways in aggressive cancers are an exciting area of research. Mutations in the MLL gene cause aggressive incurable leukemias. Benito et al. show that MLL leukemias are highly sensitive to BCL-2 inhibitors, especially when combined with drugs that target mutant MLL complex activity.
وصف الملف: application/pdf
اللغة: English
تدمد: 2211-1247
DOI: 10.1016/j.celrep.2015.12.003
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::3dd1d092c94d5a5cc8fdb3ae74b966d4Test
حقوق: OPEN
رقم الانضمام: edsair.pmid.dedup....3dd1d092c94d5a5cc8fdb3ae74b966d4
قاعدة البيانات: OpenAIRE
الوصف
تدمد:22111247
DOI:10.1016/j.celrep.2015.12.003